JP2011503164A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503164A5
JP2011503164A5 JP2010533659A JP2010533659A JP2011503164A5 JP 2011503164 A5 JP2011503164 A5 JP 2011503164A5 JP 2010533659 A JP2010533659 A JP 2010533659A JP 2010533659 A JP2010533659 A JP 2010533659A JP 2011503164 A5 JP2011503164 A5 JP 2011503164A5
Authority
JP
Japan
Prior art keywords
sample
subject
pge
level
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010533659A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503164A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2008/003856 external-priority patent/WO2009063226A2/en
Publication of JP2011503164A publication Critical patent/JP2011503164A/ja
Publication of JP2011503164A5 publication Critical patent/JP2011503164A5/ja
Pending legal-status Critical Current

Links

JP2010533659A 2007-11-12 2008-11-12 呼吸障害に関連する方法 Pending JP2011503164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98721707P 2007-11-12 2007-11-12
PCT/GB2008/003856 WO2009063226A2 (en) 2007-11-12 2008-11-12 Methods relating to breathing disorders

Publications (2)

Publication Number Publication Date
JP2011503164A JP2011503164A (ja) 2011-01-27
JP2011503164A5 true JP2011503164A5 (enExample) 2011-12-22

Family

ID=40342124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533659A Pending JP2011503164A (ja) 2007-11-12 2008-11-12 呼吸障害に関連する方法

Country Status (6)

Country Link
US (1) US20110008258A1 (enExample)
EP (1) EP2219736A2 (enExample)
JP (1) JP2011503164A (enExample)
CN (1) CN102036713A (enExample)
CA (1) CA2743334A1 (enExample)
WO (1) WO2009063226A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101446873B1 (ko) 2013-06-14 2014-10-06 서울대학교산학협력단 수면 무호흡증 진단용 생체 표지자 및 그 용도
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
WO2016149344A1 (en) * 2015-03-19 2016-09-22 Inspire Medical Systems, Inc. Stimulation for treating sleep disordered breathing
JP6885943B2 (ja) * 2015-12-01 2021-06-16 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． 失調性呼吸を治療する方法及び装置
US11103159B2 (en) 2016-03-04 2021-08-31 United States Of America As Represented By The Secretary Of The Air Force Exhaled breath hypoxia biomarkers
AU2019335070A1 (en) * 2018-09-06 2021-05-13 Ian Cooke Method of treating a sleep breathing disorder
CN113376386B (zh) * 2020-03-09 2025-09-02 中国科学院广州生物医药与健康研究院 一种病毒性肺炎的标志物及其应用
CN115624626B (zh) * 2022-08-15 2024-04-09 山东大学齐鲁医院 Ep3受体在脊髓损伤后神经源性膀胱防治中的应用
CN117323320B (zh) * 2023-11-20 2025-10-31 复旦大学附属中山医院 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6601580B1 (en) * 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
CA2415697A1 (en) * 2000-07-13 2002-01-24 James C. Forbes Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain
AU2003268032A1 (en) * 2002-07-29 2004-02-16 Epigenesis Pharmaceuticals, Inc. Composition and methods for treatment and screening
WO2004078113A2 (en) * 2003-03-04 2004-09-16 Pharmacia Corporation Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
US20050107349A1 (en) * 2003-07-24 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
WO2005027853A2 (en) * 2003-09-19 2005-03-31 University Of Louisville Research Foundation Inc Method for treating snoring and sleep apnea with leukotriene antagonists
FR2862873A1 (fr) * 2003-12-01 2005-06-03 Pf Medicament Utilisation des acides gras polyinsatures omega 3 dans l'apnee du sommeil
WO2006019984A2 (en) * 2004-07-15 2006-02-23 Yale University Compositions, methods and kits for the diagnosis and treatment of sudden infant death syndrome
DK1629850T4 (da) * 2004-08-24 2013-07-01 Nutricia Nv Næringssammensætning indeholdende ufordøjelige oligosaccharider
WO2006033965A2 (en) * 2004-09-16 2006-03-30 The Trustees Of The University Of Pennsylvania Nadph oxidase inhibition pharmacotherapies for obstructive sleep apnea syndrome and its associated morbidities
US7488291B2 (en) * 2005-09-28 2009-02-10 Medtronic, Inc. Methods for detecting and monitoring sleep disordered breathing using an implantable medical device
US8076315B2 (en) * 2005-10-14 2011-12-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
US20100074896A1 (en) * 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors

Similar Documents

Publication Publication Date Title
Seravalle et al. Sympathetic nervous system, sleep, and hypertension
Chapman et al. Mechanisms of airway hyper‐responsiveness in asthma: the past, present and yet to come
Kosseifi et al. The association between obstructive sleep apnea syndrome and microvascular complications in well-controlled diabetic patients
Kim et al. Predictors for presence and severity of obstructive sleep apnea in snoring patients: significance of neck circumference
Stone et al. Symptoms of sleep-disordered breathing in children with nocturnal enuresis
Inami et al. Links between sleep disordered breathing, coronary atherosclerotic burden, and cardiac biomarkers in patients with stable coronary artery disease
Shen et al. IL-33/ST2 mediating systemic inflammation and neuroinflammation through NF-kB participated in the neurocognitive impairment in obstructive sleep apnea
CN102036713A (zh) 涉及呼吸障碍的方法
Mutlu et al. Serum YKL-40 level is correlated with apnea hypopnea index in patients with obstructive sleep apnea sindrome
Bourjeily et al. Central sleep apnea in pregnant women with sleep disordered breathing
Al-Saleh et al. Sleep-disordered breathing in children with cardiomyopathy
Jiang et al. Tumour necrosis factor-α/interleukin-10 ratio in patients with obstructive sleep apnoea hypopnoea syndrome
Alatas et al. Obstructive sleep apnea syndrome in patients with chronic idiopathic urticaria
Passalacqua et al. Allergy and the lung
Longobardi et al. Bronchial asthma in the elderly patient
Kaštelan et al. Neuro-ophthalmological disorders associated with obstructive sleep apnoea
Binar et al. A new surgical technique versus an old marker: can expansion sphincter pharyngoplasty reduce C-reactive protein levels in patients with obstructive sleep apnea?
Shi et al. Up-to-date advance in the relationship between obstructive sleep apnea and heart failure: a narrative review
Kurt et al. Serum cardiotrophin-1 and IL-6 levels in patients with obstructive sleep apnea syndrome
Puttur et al. Sex Differences in Lung Immunity
Frange et al. Sleep Disorders: Identifying Biomarkers and Clinical Applications
Caraballo Growth and development in pediatric obstructive sleep apnea
Greydanus Intellectual disability: Sleep disorders.
Fragoso et al. Abnormal sonic hedgehog signaling in the lung of rats with esophageal atresia induced by adriamycin
O’Donnell et al. Articles in PresS. J Appl Physiol (October 29, 2009). doi: 10.1152/japplphysiol. 01208.2009